New data shows improved overall survival for prostate cancer patients treated with FIRMAGON®

New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen progression free survival (PSA PFS) for degarelix (FIRMAGON®), a gonadotropin releasing hormone (GnRH) antagonist, compared to commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Patient care firmagon gonadotropin releasing hormone antagonist Latest News luteinising hormone-releasing hormone agonists prostate cancer prostate specific antigen progression fre Source Type: news